Scopus BioPharma Inc. (SCPS)
0.00
null (null%)
At close: Jan 14, 2025, 8:00 PM
undefined% (undefined)
| Bid | n/a |
| Market Cap | 12.63K |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.31 |
| PE Ratio (ttm) | 0 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 1,228 |
| Avg. Volume (20D) | 12,453 |
| Open | 0.00 |
| Previous Close | undefined |
| Day's Range | 0.00 - 0.00 |
| 52-Week Range | 0.00 - 0.06 |
| Beta | undefined |
About SCPS
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 16, 2020
Employees 13
Stock Exchange NASDAQ
Ticker Symbol SCPS
Website https://scopusbiopharma.com
